GSK's Avamys launched in UK
UK drug major GlaxoSmithKline's new treatment for the symptoms of allergic rhinitis Avamys (fluticasone furoate) has been launched in its home market.
The London-based firm already sells a propionate formulation of the corticosteroid for the treatment of asthma and hay fever, which lost patent protection in 2006. Avamys received marketing authorization from the European Commission last year (Marketletter January 21, 2008).
According to analysts, the Avamys product family could allow GSK to rebuild its previously-dominant allergy franchise that has been under pressure following patent expiries for the older product Flixonase/Flonase. He noted that, at peak, sales of Flixonase/Flonase exceeded $1.0 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze